



#### **MEDIA CONTACTS:**

Steve Winter, Brotman|Winter|Fried  
swinter@aboutbwfcom; 202-468-8100

Heather Mahoney, Brotman|Winter|Fried  
hmahoney@aboutbwfcom; 240-271-5762

## **Council for Federal Cannabis Regulation (CFCR) Congratulates its Science Co-Chair, Co-founder and Executive Chair of Radicle Science on Most Comprehensive US Trials Measuring Impact of CBD**

*Largest and Most Comprehensive Randomized Controlled Trial of Its Kind Helps Fill  
Gap Created by Limited Real-World Evidence on Public Understanding and Use*

**WASHINGTON, D.C.** -- According to a recent survey by data research and control management company **Invisibly**, nearly 60 percent of all Americans have no viable understanding of **CBD**. By and large, they don't know what it stands for, what it means, nor what it does.

A colloquial contraction for cannabidiol, CBD is a chemical compound found in the same plant that produces cannabis (marijuana) and hemp. Naturally occurring and fully-holistic, CBD is now widely used in oils, topicals, and ingestibles for wellness purposes and other physical and mental need states.

Through a survey of more than a thousand Americans designed to shed light on our population's understanding of these products, 62 percent have never used any iteration of the product, and among that group, 68 percent indicated they were ignorant as to the difference between CBD and THC-infused products such as medical and recreational cannabis.

Actually, that's not surprising ... after all, there has been relatively little in the way of peer-reviewed documentation about this increasingly popular health-related supplement ... but thanks to a real-world evidence study recently launched by [Radicle Science](#), a San Diego-based, transformative healthtech B-corp, that's about to change.

Earlier this month [Radicle Science](#) announced the launch of its [Radicle ACES](#) (Advancing CBD Education and Science) [Study](#), the largest and most comprehensive randomized controlled trial of its kind, designed to capture CBD effectiveness data directly from nearly 3,000 study participants. The study has received Institutional Review Board (IRB) approval, which is generally recognized as a standard for the FDA in assuring the safety and well-being of human participants. IRB approvals are currently rare among the industry, and this further demonstrates the high-standards of this scientific study.

During the four-week trial period, scheduled to conclude in late September, participants will track consumption and effectiveness of orally-ingested CBD products from 13 major U.S. CBD brands, focusing on well-being, quality of life, and other common physical and mental need states. Radicle ACES will use validated, standardized health indices to gather health outcome data from a diverse population across a variety of ethnicities, age groups, geographies, behavioral habits, and pre-existing health conditions. The real-world evidence collected will inform scientific understanding on usage patterns, user characteristics, effectiveness across conditions, and predictors and modifiers of response.

And quite frankly, the leadership at the **Council for Federal Cannabis Regulations (CFCR)** could not be happier.

“This study represents sound, accurate, and responsible scientific research, which continues to create intelligible and inclusive pathways for CBD products,” said **Council Founder Sheri L. Orlowitz**, whose organization’s primary goal is to interface with the FDA on how to proceed with cannabis safety testing, research, and regulation on behalf of currently existing and future cannabis producers. “Studies of this magnitude are needed in order to put public health and safety first and foremost, as the entire cannabis industry is faced with federal regulation and the need for data, science and expertise. CFCR recognizes that further understanding and dialogue is needed to better align cannabis industry policy, scientific research and data, and regulatory measures. Our mission is to help bridge that gap not only through advocacy, education, and clear-cut communication but also by sharing knowledge and expertise from our international partners around the world and our eight-person science team with four PhDs.”

According to Radicle’s founding team, this study will achieve precisely that. “A rigorous scientific study of this magnitude has never before been conducted in the CBD market,” said **Pelin Thorogood, Co-founder and Executive Chair of Radicle Science**. “Radicle ACES is driven by our deep commitment to contribute to the body of evidence to support growing demand from consumers and healthcare providers.

“Given the scale, the diversity of the participant population and the wide range of high-quality commercial brands included, Radicle ACES promises to deliver rich, objective health outcome data for a variety of common health-related complaints, with the potential to offer unprecedented guidance on CBD effectiveness based on demographic or behavioral differences.” As Co-Chair of the Science and Regulatory Affairs Committee (SRA) for CFCR, Thorogood brings this perspective and expertise to the CFCR team.

The brands being tested in the [study](#) are fully supportive of this research. According to a quote from **Dr. Kenton Crowley, Director of Research and Development** who is overseeing the production of **Trokie**, one of the 13 brands integrated into the study, “the collaboration between Radicle Science, academic medicine and therapeutically-focused cannabinoid brands makes this trial particularly exciting. We are thrilled to be a part of a rigorous investigation into how Trokie and other clinically relevant CBD products can improve the lives of consumers and also hopefully expand the avenues for more clinical cannabinoid research.” The other brands included in the trial include ALTWELL, Charlotte’s Web, Columbia Care, Healer, Lord Jones, Maven Hemp, MD FARMA, Peels, Prospect Farms, PURAURA Naturals from Enhanced Botanicals, Rae Wellness and Verséa Wellness.

For additional information, please visit [uscfcf.org](http://uscfcf.org).

####

#### **ABOUT CFCR**

The Council for Federal Cannabis Regulation (CFCR) is 501(c)(3) and 501(c)(4) non-profit that serves as a forum in which stakeholders -- both from the federal government and industry -- can analyze and support the creation of informed, intelligible, and inclusive federal laws and regulations to govern the cannabis industry. CFCR exists to educate, advocate, and communicate. For additional information please visit [www.uscfcf.org](http://www.uscfcf.org) and follow us on social media @USCFCR.

#### **ABOUT RADICLE SCIENCE**

[Radicle Science](#) is a transformative healthtech B-corp offering the first ever path to natural product validation at scale. Radicle Science disrupts the traditional clinical trial model by combining the reach of a market research company, the scientific rigor of a research university, and the agility of a tech company. Operating at the intersection of big data, digital health and natural products, Radicle Science leverages a proprietary data analytics platform and a virtual, direct-to-consumer (D2C) model to deliver objective health outcome data across diverse populations and conditions. Our Radicle Vision is a future where affordable, accessible, natural health products are trusted by patients, recommended by healthcare providers, reimbursed by insurance, and used as widely as pharmaceutical drugs. To learn more, please visit [www.radiclescience.com](http://www.radiclescience.com) and follow their [LinkedIn page](#).